JBM Healthcare gets bitter pill from investors on anemic performance
Shares of the over-the-counter traditional Chinese medicine company tumbled after it reported sequential revenue and profit declines in the second half of its fiscal year Key Takeaways: JBM Healthcare’s profit…
BRIEF: Baiyunshan invests $105 million for 11% of NanJing Pharma
Guangzhou Baiyunshan Pharmaceutical Holdings Co. Ltd. (0874.HK; 600332.SH) said on Sunday it paid 749 million yuan ($105 million) via its Guangzhou GP Fund II subsidiary for 11.04% of NanJing Pharmaceutical…
Baiyunshan serves up high dividend in lieu of vanilla results
Profits from the company’s Great Health segment rose 14% in the first half of 2025, primarily driven by strong results for its popular Wanglaoji herbal tea Key Takeaways: Baiyunshan’s revenue…
Recent Articles
BRIEF: Baiyunshan invests $105 million for 11% of NanJing Pharma
0874.HK
600332.SHG
600713.SHG
Baiyunshan serves up high dividend in lieu of vanilla results
0874.HK
600332.SHG
RELATED ARTICLES
-
Tong Ren Tang kicks off IPO leveraging time-honored medicinal brand to offer healthcare
2667.HK - Chinese medicine firm seeks elusive elixir of IPO success
- Good Doctor Cloud Healthcare’s ailing margins belie uninspired new listing
- Yidu Tech swings to profit as AI healthcare edges toward viability
- Cango eyes high-performance computing scale-up after turning a tight corner
- Slowing takeout dining wars leave Luckin with bitter aftertaste
-
BRIEF: Distinct Healthcare launches $41 million Hong Kong IPO
2677.HK
